###### Key messages

-   The condom and the oral contraceptive pill continue to be the most commonly used contraceptive methods in Britain.

-   A significant increase in long-acting reversible contraceptive (LARC) use has been observed, particularly among women under 25 years of age, suggesting strategies to increase uptake have been successful.

-   A significant increase was also observed in the proportion of women reporting no current contraceptive use.

Introduction {#s1}
============

Unintended pregnancy continues to be a public health problem in Europe.[@R1] In Britain, an estimated one in five pregnancies are not planned.[@R2] While contraception can prevent unintended pregnancy, the effectiveness and continuation rates of available methods vary greatly. The last half century has seen major changes in patterns of fertility and its control. The interval between onset of sexual activity and childbearing has widened, and desired and actual family size has decreased, thus increasing the time period during which effective contraception is most required.[@R3]

The 21st century has seen a range of policy-related initiatives aimed at reducing rates of unintended pregnancy in Britain, many of them specifically focused on increasing awareness and uptake of long-acting reversible methods of contraception (LARC). Mounting evidence of the cost effectiveness of LARC methods prompted the National Institute for Health and Care Excellence (NICE) to publish guidance in 2005 recommending the increased use of such methods.[@R4] The income of general practitioners was linked to performance against Quality and Outcome Framework (QOF) goals, and in 2009 a new set of indicators on contraception was introduced, including provision of information about LARC methods.[@R5]

Thus far, there have been few national data with which to assess progress towards the goals of these initiatives. Efforts to do so have relied on routinely collected data such as prescribing rates in primary care which provide information about rates of method use, but not users.[@R7] Survey data on specialist contraceptive service use has reported an increase in LARC method use over the last decade.[@R8] However, it offers limited opportunities to explore correlates of use associated with user sociodemographic characteristics and sexual and reproductive behaviour, and does not include women who obtain methods from other suppliers, such as general practice and pharmacies.

Data from the two most recent National Surveys on Sexual Attitudes and Lifestyles (Natsal-2 and Natsal-3) provide an opportunity to examine the mix of contraceptive methods used by women in Britain at the start of the 21st century and to describe changes in patterns of use. Specifically, the data enable us to determine whether there has been a change in the use of the most effective contraceptive methods, how this varies between subgroups of women, and with what apparent effect on use of other methods. In this article we describe trends in contraceptive method use in Britain between Natsal-2 and Natsal-3 with the aim of exploring how changes in patterns of fertility and in policy may have impacted on method use, in particular LARC methods.

Methods {#s2}
=======

Natsal is a clustered and stratified probability survey of the sexual attitudes and behaviours of men and women resident in Britain. It has been carried out roughly decennially in 1990 (Natsal-1), 1999--2000 (Natsal-2) and 2010--2012 (Natsal-3). Data from Natsal-1 have not been included in this analysis since contraceptive implants were not available in Britain until 1991 and the levonorgestrel-releasing intrauterine system (LNG-IUS) was not marketed until 1995. In Natsal-2, 11 161 participants aged 16--44 years (6399 women and 4762 men) were interviewed; Natsal-3 included 15 162 participants aged 16--74 years (8869 women and 6293 men). Households within postcode sectors, the primary sampling units, were selected and one eligible adult at the address randomly selected. Data were weighted to take account of unequal probabilities of selection and non-response. Computer-assisted personal interviews (CAPI) were used for data collection and computer-assisted self-interviews (CASI) were used for more sensitive questions. The response rates for Natsal-2 and Natsal-3 were 65.4% and 57.7%, respectively, and in Natsal-3 the co-operation rate (ie, of all eligible addresses contacted) was 65.8%. Full details of the survey methods have been described elsewhere.[@R9]

In this article we use responses to the Natsal question about contraceptive methods currently used: "Which would you say is your most usual method these days?". Participants who reported in CASI ever having had sexual intercourse with an opposite sex partner were presented with a list of different contraceptive methods to select. Analysis was first confined to women aged under 45 years who reported ever having had vaginal sex to provide population estimates on current use of different contraceptive methods and to investigate changes in use between Natsal-2 and Natsal-3. When examining user characteristics by contraceptive method use the analysis was then confined to women who had vaginal sex in the last year and those who were not pregnant at the time of interview. Although participants were asked in Natsal-3 whether they or their partner were trying to conceive and whether they had had a hysterectomy, these questions were not asked in Natsal-2. Therefore, women in Natsal-3 who reported that they were trying to conceive or had had a hysterectomy were kept in the analysis to allow comparison between the two surveys.

Contraceptive methods were characterised by level of effectiveness into: Most effective (female/male sterilisation, intrauterine device (IUD), intrauterine system (IUS), implant); Effective (oral contraceptive pill, injection, transdermal patch); Less effective (condom, Femidom, cap, spermicides, rhythm method, withdrawal) and No method used. The categorisation was based on typical rather than perfect user failure rates.[@R10] In analysis, the categories were grouped hierarchically so that if more than one method was reported, the more effective method took precedence. The injectable contraceptive depot medroxyprogesterone acetate (DMPA, Depo-Provera) was not included in the most effective method category, despite being categorised as a LARC by NICE, since this method is generally placed in the same tier of effectiveness as oral contraceptive pills. Although the contraceptive effect of injections lasts 12 weeks, the method can be stopped without the need to see a health provider and discontinuation rates are similar to those of oral contraception. The use of DMPA, in contrast to other LARCs, has not been shown to reduce unintended pregnancy rates.[@R11] When examining user characteristics, permanent methods (ie, female and male sterilisation) and LARC methods were analysed separately.

Usual contraceptive method use was examined by demographic variables: age, ethnicity, religion, academic qualifications, Index of Multiple Deprivation, and relationship status. We also examined sexual and reproductive health behaviour variables: sexually transmitted infection (STI) in the last year, frequency of sex in the last 4 weeks, and parity.

All statistical analyses were conducted using the Stata (version 13) (StataCorp, College Station, TX, USA) survey commands, in order to account for the weighting, clustering, and stratification of the survey data. Prevalence of method use was estimated. Bivariate analysis was used to describe associations between method use and selected sociodemographic characteristics and sexual and reproductive behaviours. The odds ratios (ORs) for the difference in prevalence between Natsal-2 and Natsal-3 were examined; 95% confidence intervals (95% CIs) are used throughout.

Results {#s3}
=======

In Natsal-3, 5237 of the 5842 women aged 16--44 years reported that they had ever had vaginal intercourse. Over three-quarters of these women (76.4%, 95% CI 75.0 to 77.7) reported current use of any contraception. In Natsal-2, 5178 of the 6399 women reported that they had ever had vaginal intercourse. Current contraceptive use was reported by 83.5% (95% CI 82.4--84.5) of women, significantly higher than the prevalence observed in Natsal-3. The condom and oral contraceptive pill were the methods most commonly used by women and this was observed in Natsal-2 and Natsal-3 ([table 1](#T1){ref-type="table"}). In the most effective contraceptive method category, male sterilisation was replaced by implants as the most commonly cited method over the last decade (8.9% and 0.3%, respectively, in Natsal-2 compared with 4.9% and 5.4%, respectively, in Natsal-3). Use of the patch, female condom, cap or diaphragm and spermicides was very low in both surveys. Around one in five women reported in Natsal-3 that they had not used any method of contraception in the last year, however 7.4% (95% CI 6.6 to 8.3) of all women reported no vaginal sex in the last year, 7.6% (95% CI 6.8 to 8.5) were trying to conceive, 4.4% (95% CI 3.8 to 5.0) were pregnant at the time of interview and 1.4% (95% CI 1.0--2.0) had had a hysterectomy. Women were not asked in Natsal-2 whether they were trying to conceive or if they had had a hysterectomy.

###### 

Usual use of contraceptive methods among women aged 16--44 years who ever reported vaginal intercourse: Natsal-2 and Natsal-3

  Denominator (unweighted, weighted)\*     Natsal-2: usual use   Natsal-3: usual use                
  ---------------------------------------- --------------------- --------------------- ------------ ---------------------
  Most effective methods                   1141, 1077            21.5 (20.4 to 22.8)   944, 762     21.1 (19.7 to 22.6)
   Intrauterine device                     265\. 221             4.4 (3.9 to 5.0)      230\. 187    5.2 (4.4 to 6.1)
   Hormonal intrauterine system (Mirena)   44, 35                0.7 (0.5 to 1.0)      105, 96      2.6 (2.1 to 3.3)
   Implant                                 15, 14                0.3 (0.2 to 0.5)      348, 194     5.4 (4.8 to 6.0)
   Male sterilisation                      445, 446              8.9 (8.1 to 9.8)      162, 177     4.9 (4.1 to 5.8)
   Female sterilisation                    382, 370              7.4 (6.6 to 8.3)      106, 114     3.2 (2.6 to 3.9)
  Effective methods†                       1940, 1747            34.9 (33.5 to 36.4)   1953, 1194   33.1 (31.6 to 34.6)
   Pill                                    1769, 1599            32.0 (30.6 to 33.4)   1741, 1064   29.5 (28.1 to 30.9)
   Injections                              171, 148              3.0 (2.5 to 3.5)      210, 128     3.6 (3.0 to 4.1)
  Less effective methods†                  1641, 1417            28.3 (27.0 to 29.7)   1356, 940    26.1 (24.6 to 27.5)
   Male condom                             1360, 1184            23.7 (22.4 to 25.0)   1229, 833    23.1 (21.7 to 24.5)
   Cap/diaphragm†                          45, 31                0.6 (0.4 to 0.9)      --           --
   Natural family planning (rhythm)        104, 85               1.7 (1.3 to 2.1)      37, 35       1.0 (0.7 to 1.4)
   Withdrawal                              173, 150              3.0 (2.6 to 3.5)      92, 75       2.1 (1.6 to 2.6)
  No method used                           1030, 826             16.5 (15.5 to 17.6)   1173, 853    23.6 (22.3 to 25.0)
   No vaginal sex in last year             463, 309              6.0 (5.4 to 6.7)      408, 271     7.4 (6.6 to 8.3)

\*Denominator is Natsal population aged 16--44 years, excluding those who have never had vaginal intercourse.

†Numbers too small for patch (effective), cap/diaphragm in Natsal-3 (less effective), female condom (less effective), spermicides (less effective)

No significant difference was observed in the odds of use of the most effective and effective methods between the surveys ([figure 1](#F1){ref-type="fig"}). However, in the most effective category the overall change in likelihood of use masks considerable differences in contraceptive methods used within this category, particularly the move from permanent to reversible methods. Increases observed in odds of reporting current use of implants (OR 19.95, 95% CI 10.92 to 36.45) and the IUS (OR 3.84, 95% CI 2.57 to 5.74) were offset by a significant decline in odds of reporting use of male and female sterilisation (OR 0.53, 95% CI 0.43 to 0.66 and OR 0.41, 95% CI 0.31 to 0.53, respectively). Significant increases in the likelihood of reporting that they were currently not using any method were observed between Natsal-2 and Natsal-3 (OR 1.61, 95% CI 1.40 to 1.85).

![Changes between Natsal-2 and Natsal-3 in the odds of usual contraceptive method use in the last year: sexually experienced\*Reporting having ever had vaginal intercourse among women aged 16--44 years. CI, confidence interval; OR, odds ratio.](bmjsrh-2019-200474f01){#F1}

The demographic and lifestyle characteristics by contraceptive method effectiveness category or non-method use among women who reported vaginal sexual intercourse in the last year for Natsal-3 are shown in [table 2](#T2){ref-type="table"}. Women who reported current use of female or male sterilisation were significantly more likely to be older (≥35 years), married and have two or more children. Women identifying as 'white 'were significantly more likely to report use of sterilisation when compared with Asian women and women of mixed or other ethnicity. The only significant association found among LARC users was that they were more likely to have had two or more children.

###### 

Prevalence of usual contraceptive method use in the last year by sociodemographic and lifestyle characteristics: Natsal-3

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristics\                                         Denominator\* (weighted/unweighted)   Most effective: sterilisation   Most effective: LARC   Effective             Least effective       No method used
  Total                                                                                                                                                                                             
  -------------------------------------------------------- ------------------------------------- ------------------------------- ---------------------- --------------------- --------------------- ---------------------
  **Sociodemographic**                                                                                                                                                                              

  Age (years)                                                                                                                                                                                       

   16--17                                                  244 to 118                            0.0                             14.5 (10.5 to 19.7)    47.5 (40.8 to 54.2)   33.2 (26.9 to 40.0)   4.9 (2.8 to 8.3)

   18--19                                                  353 to 185                            0.0                             12.3 (9.0 to 16.6)     56.0 (50.2 to 61.5)   25.8 (21.1 to 31.1)   5.9 (3.8 to 9.1)

   20--24                                                  928 to 544                            0.3 (0.1 to 1.0)                13.7 (11.3 to 16.4)    50.4 (46.7 to 54.0)   24.1 (21.0 to 27.5)   11.5 (9.4 to 14.1)

   25--29                                                  1162 to 577                           2.9 (2.1 to 4.0)                13.2 (11.0 to 15.7)    44.9 (41.7 to 48.1)   23.8 (20.8 to 27.1)   15.2 (13.0 to 17.7)

   30--34                                                  702 to 447                            4.0 (2.7 to 6.0)                14.2 (11.5 to 17.4)    36.3 (32.6 to 40.1)   24.0 (20.6 to 27.7)   21.6 (18.5 to 25.0)

   35--44                                                  892 to 1074                           18.5 (15.8 to 21.6)             15.4 (13.0 to 18.2)    20.8 (18.1 to 23.7)   22.6 (19.8 to 25.7)   22.7 (20.0 to 25.6)

  Ethnicity                                                                                                                                                                                         

   White                                                   3990 to 2772                          9.9 (8.6 to 11.2)               14.4 (13.1 to 15.8)    37.3 (35.5 to 39.0)   22.3 (20.8 to 24.0)   16.1 (14.8 to 17.5)

   Asian/Asian-British                                     214 to 181                            2.9 (1.0 to 8.0)                8.7 (5.3 to 13.9)      12.0 (8.0 to 17.6)    41.2 (34.1 to 48.7)   35.2 (28.0 to 43.1)

   Black/Black-British                                     122 to 94                             4.1 (1.1 to 13.4)               18.9 (12.1 to 28.3)    21.6 (14.2 to 31.4)   32.5 (23.1 to 43.5)   23.0 (15.4 to 32.8)

   Mixed/other                                             193 to 132                            1.4 (0.4 to 4.8)                15.4 (9.9 to 23.3)     35.7 (28.2 to 44.0)   27.0 (20.2 to 35.1)   20.5 (14.8 to 27.5)

  Religion                                                                                                                                                                                          

   None                                                    2597 to 1720                          8.7 (7.3 to 10.4)               14.4 (12.9 to 16.1)    39.2 (37.1 to 41.3)   22.0 (20.1 to 23.9)   15.7 (14.1 to 17.4)

   Christian                                               1656 to 1253                          10.2 (8.4 to 12.4)              14.5 (12.5 to 16.8)    33.2 (30.7 to 35.8)   24.3 (21.9 to 26.9)   17.6 (15.5 to 19.9)

   Muslim                                                  136 to 109                            1.3 (0.2 to 8.5)                14.4 (8.8 to 22.8)     13.7 (8.2 to 22.0)    35.1 (26.9 to 44.4)   35.5 (27.1 to 45.0)

   Hindu                                                   55 to 38                              0.0                             6.3 (1.7 to 20.3)      10.9 (4.6 to 23.7)    52.3 (38.4 to 65.8)   30.5 (19.2 to 44.8)

   Other                                                   76 to 60                              7.7% (3.1 to 18.1)              9.6% (3.8 to 22.3)     23.5 (15.5 to 34.0)   31.2 (20.6 to 44.2)   28.0 (17.6 to 41.3)

  Academic qualification†                                                                                                                                                                           

   No academic qualifications                              369 to 241                            9.9 (6.5 to 14.7)               16.0 (12.1 to 20.8)    25.7 (20.9 to 31.3)   17.6 (13.6 to 22.5)   30.8 (25.3 to 36.8)

   Qualifications typically gained at age 16 years         1512 to 1077                          15.2 (12.8 to 17.9)             15.4 (13.4 to 17.7)    33.6 (30.9 to 36.4)   18.0 (15.7 to 20.4)   17.8 (15.6 to 20.2)

   Studying for/attained further academic qualifications   2415 to 1716                          5.5 (4.3 to 6.9)                12.9 (11.3 to 14.7)    38.6 (36.5 to 40.7)   27.5 (25.4 to 29.7)   15.5 (13.9 to 17.3)

  Index of Multiple Deprivation                                                                                                                                                                     

   1--2 (Least deprived)                                   1566 to 1174                          9.8 (8.0 to 12.0)               13.3 (11.4 to 15.4)    37.2 (34.5 to 39.9)   24.6 (22.2 to 27.2)   15.1 (13.1 to 17.4)

   3                                                       895 to 642                            9.5 (7.1 to 12.5)               14.8 (12.2 to 17.8)    36.3 (32.9 to 40.0)   23.2 (20.1 to 26.7)   16.1 (13.5 to 19.2)

   4--5 (Most deprived)                                    2068 to 1369                          7.9 (6.4 to 9.8)                14.8 (13.0 to 16.9)    33.3 (30.9 to 35.8)   23.7 (21.5 to 26.1)   20.3 (18.2 to 22.5)

  Relationship status                                                                                                                                                                               

   Married                                                 1408 to 1337                          15.4 (13.3 to 17.9)             14.6 (12.5 to 16.9)    23.0 (20.8 to 25.5)   24.1 (21.6 to 26.8)   22.9 (20.5 to 25.4)

   Cohabiting, not married                                 1023 to 727                           6.3 (4.6 to 8.7)                14.7 (12.3 to 17.4)    41.9 (38.4 to 45.5)   21.6 (18.8 to 24.6)   15.5 (13.1 to 18.2)

   Previously married                                      115 to 69                             8.4 (3.7 to 18.0)               22.0 (14.6 to 31.9)    21.2 (14.7 to 29.6)   12.7 (7.9 to 19.8)    35.6 (25.5 to 47.2)

   Never married                                           1972 to 1047                          2.5 (1.6 to 3.8)                13.1 (11.4 to 14.9)    47.3 (44.7 to 49.8)   26.0 (23.7 to 28.5)   11.1 (9.6 to 12.7)

  **Sexual and reproductive health**                                                                                                                                                                

  STI in last year                                                                                                                                                                                  

   No                                                      2554 to 1750                          8.2 (6.8 to 10.0)               12.1 (10.6 to 13.7)    35.6 (33.5 to 37.7)   25.6 (23.6 to 27.7)   18.5 (16.8 to 20.4)

   Yes                                                     100 to 55                             3.7 (0.7 to 18.3)               9.0 (4.9 to 15.9)      53.1 (42.7 to 63.2)   22.7 (15.1 to 32.5)   11.5 (6.2 to 20.4)

  Frequency of vaginal sex in last 4 weeks (n)                                                                                                                                                      

   0                                                       791 to 530                            5.1 (3.2 to 7.9)                12.6 (10.1 to 15.7)    31.7 (27.9 to 35.6)   25.3 (22.0 to 28.9)   25.3 (22.0 to 29.1)

   1--4                                                    1923 to 1415                          9.3 (7.6 to 11.2)               13.1 (11.3 to 15.0)    33.0 (30.7 to 35.4)   27.2 (24.9 to 29.7)   17.4 (15.4 to 19.7)

   5--9                                                    1012 to 713                           10.9 (8.4 to 13.9)              16.8 (14.3 to 19.7)    38.1 (34.8 to 41.4)   20.1 (17.4 to 23.1)   14.1 (11.7 to 17.0)

   10+                                                     772 to 504                            9.2 (6.7 to 12.5)               15.6 (12.6 to 19.0)    42.3 (38.1 to 46.5)   19.2 (15.8 to 23.1)   13.8 (11.1 to 16.9)

  Children (n)                                                                                                                                                                                      

   0                                                       2075 to 1316                          1.1 (0.7 to 1.8)                10.0 (8.6 to 11.7)     48.6 (46.2 to 51.1)   27.2 (24.9 to 29.5)   13.0 (11.4 to 14.9)

   1                                                       934 to 591                            3.3 (2.0 to 5.4)                13.9 (11.3 to 16.9)    31.4 (28.1 to 34.9)   23.7 (20.7 to 27.0)   27.7 (24.4 to 31.3)

   2+                                                      1520 to 1277                          19.6 (17.1 to 22.3)             18.7 (16.5 to 21.2)    23.4 (21.2 to 25.9)   20.8 (18.4 to 23.3)   17.5 (15.4 to 19.8)
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Denominator women \<45 years who had vaginal sex in the last year, not pregnant.

†Ages \>16 years.

LARC, long-acting reversible contraceptive; STI, sexually transmitted infection.

Use of effective methods peaked in the 18--19 years age group (56.0%, 95% CI 50.2 to 61.5). Asian women were significantly less likely than White women to report effective contraceptive method use, and usual use was significantly lower among women of Muslim or Hindu faith compared with Christians or those with no faith. Usual effective method use was significantly higher among women studying for or with academic qualifications compared with those with fewer qualifications. Prevalence was highest among unmarried women, including those cohabiting. Those with two or more children were significantly less likely to use these methods. Prevalence increased incrementally with frequency of sex and women using these methods were significantly more likely to report an STI in the last year.

Users of the less effective methods were significantly more likely to be younger (use peaking in the 16--17 years age group). There were differences in the ethnic and religious profiles of users. Around half of Asian women (41.2%, 95% CI 34.1 to 48.7) compared with 22.3% (95% CI 20.8 to 24.0) of White women reported current use of less effective methods. Higher prevalence of less effective use was reported among participants of Muslim and Hindu faiths. Use of less effective methods was significantly higher among those who were currently studying or had achieved higher academic qualifications, those having less frequent sex and those without any children.

Among those who reported vaginal sex in the last year and were not currently pregnant, 17.5% (95% CI 16.3-18.9) reported no current method, although this reduced to 9.0% (95% CI 7.9 to 10.3) when those who were trying to conceive or had had a hysterectomy were excluded from the analysis. The proportion of those who reported not currently using any contraceptive method increased incrementally with age, being reported by nearly a quarter of women aged 35--44 years (22.7%, 95% CI 20.0 to 25.6). No method use was highest among participants of Asian ethnicity and among those of Muslim and Hindu faith. Women without academic qualifications were significantly more likely to report no method use, and those living in more deprived areas were significantly more likely to report non-use when compared with women living in the least deprived areas. Non-use was also significantly higher among those who were currently or previously married, those who reported no vaginal sex in the last 4 weeks, and those with one child.

There was more than a 10-fold increase in under-25-year-olds reporting current use of a LARC method from Natsal-2 to Natsal-3 (OR 11.35, 95% CI 3.23 to 39.87) compared with women 40 years and above ([figure 2](#F2){ref-type="fig"}). A four-fold increase over time was seen among the 25--29 years group. Use significantly increased among women who had never married compared with married women, (OR 3.41, 95% CI 2.29--5.09). A statistically significant increase was observed in the odds of use among those with fewer qualifications compared with those with more qualifications. A significant decline in the odds of current LARC use was observed among women with children compared with those with no children. No statistically significant differences were observed between the two surveys in relation to ethnicity, religion, and area of deprivation.

![Changes between Natsal-2 and Natsal-3 in the odds of long-acting reversible contraceptive (LARC) method use in the last year by demographic and lifestyle characteristics: sexually active\* women aged 16--44 years.\*Reporting vaginal sex in the last year. CI, confidence interval; FE, further education; OR, odds ratio.](bmjsrh-2019-200474f02){#F2}

Discussion {#s4}
==========

In both Natsal-2 and Natsal-3, one in five women reported that they were currently using a contraceptive method in the most effective category. The transition from less effective to most effective use overall corresponded with increased age, marriage, and having two or more children. No increase in overall most effective method use was observed among women, but significant increases in the odds of the implant and IUS use were seen between the two surveys. Increases in LARC use were particularly evident among the under-25s.

An increase in the use of LARC and a decline in sterilisation have been observed in other countries.[@R12] In our analysis, while significant declines in male and female sterilisation were observed from 1999 to 2009, increased use of LARC was not sufficient to increase overall prevalence of most effective method use. Use of any contraceptive method is more cost effective than no method use; however, LARC methods have been found to be the most cost effective.[@R14] A benefit of LARC methods over sterilisation is their reversibility, thus reducing both personal and financial costs for the small number of women who request reversal of sterilisation, and their greater suitability for younger people wanting highly effective protection against pregnancy. Lack of awareness and concerns about insertion and removal procedures, side effects and perceived 'permanency' of these methods are still barriers to uptake of LARC,[@R16] but increasing accessibility and women's knowledge (and removing any misconceptions) of these methods has been shown to have a significant impact on their uptake.[@R19] Prescribing practice has also been found to be responsible for narrowing contraceptive choice.[@R20] The large increase in most effective method use among the under-25s is promising and is an indication that knowledge and attitudes among both users and professionals may have shifted.

The oral contraceptive pill and condom are still the methods most commonly used, particularly among the young. Condoms are easily accessible and have the added benefit of STI protection. We grouped methods by the protection they offered against pregnancy rather than STIs. Condoms were grouped in the less effective category as we based the groups on typical failure rates, but if they are used consistently and correctly they offer good protection from both pregnancy and STIs. Nearly three-quarters of women report that they use condoms for exclusively pregnancy prevention compared with just over one in ten who use them exclusively for STI prevention.[@R22] More effective contraceptive use could potentially have a negative consequence on STI rates if use of condoms declines as a consequence, so it is important that any education about these methods is given alongside messages on reducing risk of STIs. For the most part, it is still women who take responsibility for pregnancy prevention, and couples tend to move from condom to pill use as the relationship becomes more permanent and trusting.[@R23]

Contraceptive prevalence is high in Britain compared with other developed countries.[@R24] However, another trend observed from our data was a significant increase between Natsal-2 and Natsal-3 in no method use among women who have had vaginal sex in the last year and were not currently pregnant. In their national probability survey of contraceptive behaviours among French women, Moreau and colleagues argue that even small changes in unmet contraceptive need contribute to the largest effects on unintended pregnancy rates within the general population.[@R25] In Natsal-3, the highest prevalence of non-use (and less effective method use) among Asian participants and those of Muslim and Hindu faiths may be influenced by cultural norms around fertility, including less access to sexual and reproductive services, in some communities.[@R26] It is notable that non-use was also higher among those without any academic qualifications and those living in more deprived areas, both factors which have been associated with unplanned pregnancy.[@R3] While teenage pregnancies remain at a record low, abortion rates among women aged 25 years and older are rising and at a 10-year high.[@R28]

A strength of this study is that it provides national prevalence and trends at a population level. However, there are limitations that should be considered when interpreting the findings. The aim of our analysis was to present prevalence by contraceptive effectiveness category or non-use and to examine trends which would help inform public health initiatives and service provision. Therefore, we looked at crude, actual rates without adjustment for confounders to explore risk factors. Given the cross-sectional design of Natsal we could not reliability establish chronology and ascertain risk of unplanned pregnancy and current contraceptive method use or non-use. Numerous other socioeconomic and lifestyle trends including, perhaps most notably, the increase in the proportion of women entering higher education in Britain during the period in question, have had the potential to contribute to the increase in the use of LARC. Differences in population characteristics between Natsal-2 and Natsal-3 have been noted in other analyses, such as a decline in the proportion of women who are married or cohabiting.[@R30] Although women were asked in Natsal about what sources they use to obtain contraceptive supplies they were not asked where they obtained specific methods, so it is not possible to determine who got what where and how this may have changed over time.[@R27]

Even a modest increase in effective contraceptive use results in financial savings and health gain.[@R31] Eight in 10 women in the UK aged between 16 and 44 years report that they are currently using a method of contraception, demonstrating the need for accessible contraceptive services. The analysis in this article suggests some success in the first decade of the 21st century in widening access to LARC methods across the sociodemographic spectrum. However, since 2014 QOF payments to counsel pill and patch users about LARC methods have been scrapped and since 2015 community contraceptive services have faced major cuts to funding.[@R32] Findings from Natsal-4 will be due from 2023 and will help us better understand the impact of changes in population demographics and lifestyles and service cuts on contraceptive use and reproductive outcomes.
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